Praxis Precision Medicines, Inc.
praxismedicines.comWhat Do They Do?
Develops small-molecule drugs and antisense medicines for patients with epilepsy and movement disorders.
10-K for FY2025, filed Feb 19, 2026We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights…View ↗
Cerebrum™, our small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of…View ↗
Our platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$83.7MView ↗
- ▲ +18% (Loss)
- vs −$71.1M in Q2 FY2025
-
Jul 7, 2026
Praxis and Remagine agreed to develop an ulixacaltamide patch
The collaboration applies Remagine’s transdermal dosing platform to ulixacaltamide alongside Praxis’s oral program.
Sources
8-K, filed Jul 7, 2026
On July 7, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the Company entered into a research collaboration and…View ↗
-
Jul 2, 2026
Praxis dismissed Ernst & Young and appointed KPMG as its auditor
Sources
8-K, filed Jul 2, 2026
On June 29, 2026, the Audit Committee of the Board of Directors (the "Audit Committee") of Praxis Precision Medicines, Inc. (the "Company")…View ↗
Who Do They Compete With?
Competes with SK-Pharma, Xenon Pharmaceuticals, Biohaven Pharmaceuticals, Lundbeck, and Stoke Therapeutics
10-K for FY2025, filed Feb 19, 2026Approved therapies for ET, such as propranolol, and off-label therapies, such as primidone. Sodium channel blocker or similar ion…View ↗
Loading...
